Project Details
Projekt
Dissecting AML treatment response to FLT3 inhibitors by single-cell sequencin (B12*)
Subject Area
Hematology, Oncology
Term
from 2020 to 2024
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 217328187
The constitutive activation of the FLT3 tyrosine kinase in AML via internal tandem duplications can be therapeutically targeted with the multi-kinase inhibitor midostaurin or the FLT3 specific drug gilteritinib, which are compared in a randomized phase III clinical trial (HOVON 156 / AMLSG 28-18). Differences between the two drugs as well as intra-tumor heterogeneity and its changes during this treatment are resolved in a comprehensive multi-omics single-cell sequencing analysis. It will reveal molecular features of leukemia cell subgroups, their response to treatment as well as changes of non-malignant cells in the microenvironment.
DFG Programme
Collaborative Research Centres
Applicant Institution
Universität Ulm
Project Heads
Professorin Dr. Konstanze Döhner; Professor Dr. Karsten Rippe
